A retrospective analysis of data from a cohort of patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were treated with highly active antiretroviral therapy (HAART) at 3 infectious diseases units in northern Italy was performed. While the patients were receiving HAART, CD4 + cell counts significantly increased and HIV RNA serum levels decreased. However, no significant overall changes in alanine aminotransferase (ALT) levels and HCV RNA serum levels were observed. Fifteen (4.6%) of 323 patients died within 3 years of follow-up; death was related to cirrhosis in 5 patients (1.6%). No significant difference was observed between cirrhosis-related mortality and mortality related to other causes. Patients with ALT levels 14 times the normal values at initiation of HAART showed a significant decrease in ALT levels, whereas patients with normal ALT levels at initiation of HAART showed a significant increase over time, suggesting that HAART may have long-term beneficial or detrimental effects, depending on patient characteristics.
Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality among HIV-infected individuals since 1996 [1, 2] . However, hepatitis C virus (HCV) infection is frequently encountered in HIV-infected patients, because the 2 viruses have routes of transmission in common [3, 4] . Improved survival rates among HIV-infected people may lead to an increase in mortality related to progression of chronic hepatitis C and liver failure. Furthermore, rapid progression to cirrhosis has been reported in patients coinfected with HIV and HCV [5] [6] [7] .
It has been hypothesized that immune restoration induced by HAART may lead to a better control of HCV replication, because progression of HCV disease has been shown to be related to the degree of immunosuppression [8, 9] . Furthermore, a possible interaction between protease inhibitors and HCV protease has been demonstrated by a molecular enzymatic model [10] . In contrast, HAART may worsen the outcome of HCV disease, both through enhancement of immune-induced liver damage [11, 12] and through protease inhibitor-induced hepatotoxicity [13] .
Contrasting data have been reported on the course of HCV viremia and liver disease in HIV-positive patients treated with HAART. Several studies showed no significant changes in HCV RNA and alanine aminotransferase (ALT) serum levels during HAART [14] [15] [16] [17] . Other investigators reported transient or persistent increase in HCV load during HAART [18, 19] , whereas clearance of HCV RNA serum levels during HAART was reported only by Fialaire et al. [20] .
However, the number of patients evaluated in these studies was limited, ranging from 10 to 34, and followup periods were short (only 1 study had a follow-up period of 11 year). As a consequence, we were prompted to retrospectively evaluate data from a large cohort of patients followed up for as long as 3 years in 3 different Italian institutions, to learn about the long-term effects of HAART on liver function and HCV disease.
PATIENTS AND METHODS
This study was carried out in 3 different infectious disease units in northern Italy to evaluate the clinical evolution of HCV infection in a cohort of 323 HIV-positive patients who were treated with HAART. The cases of all HCV-and HIV-positive and hepatitis B surface antigen-negative adult patients who had been treated with HAART for at least 6 months and for whom the follow-up period was at least 2 years were retrospectively evaluated, starting from initiation of HAART.
Medical records were reviewed, and the following data were collected from the charts at 6-month intervals: the type of ongoing antiretroviral therapy; ALT serum levels, bilirubin levels, albumin levels, and prothrombin time; presence of ascites or hepatic encephalopathy; CD4 ϩ cell count; HIV RNA count;
and HCV RNA count. The Child-Pugh score for cirrhosis was also evaluated for each data collection point. The outcomes we considered were death; progression of cirrhosis; and changes in ALT levels, CD4 ϩ cell count, HIV load, and HCV load. Data for patients with 12 years of follow-up were evaluated through month 36 after initiation of HAART. Data were entered into a database to allow us to evaluate different groups of patients. Statistical analysis was done by 1-way analysis of variance, adjusted using the Bonferroni multiple-comparison test, and by t test. Analysis of survival curve was performed using the log-rank test.
RESULTS

Study population.
The characteristics of the patient population that we evaluated are described in (log-rank test). P p . 19 
low CD4
ϩ cell counts and high HIV viremia. A very high variability in ALT levels at initiation of HAART was found. In particular, 92 patients (28.5%) had normal ALT levels, whereas only 27 patients (8.4%) had ALT levels 14 times the normal value. Finally, it should be noted that these patients were generally treated with HAART for a long time, close to the duration of the follow-up period. Survival. Survival rates in the patient population are illustrated in figure 1. No significant difference was observed between mortality related to cirrhosis and mortality related to other causes, including AIDS ( ). A low overall mortality P p .19 rate was observed (15 [4.6%] of 323 patients). Five patients (1.6%) died as a result of liver failure.
Progression to cirrhosis. Progression to cirrhosis according to the Child-Pugh score was observed in 9 (2.8%) of 323 patients. These patients progressed from stage A to stage B; 1 patient showed further progression, from stage B to stage C. The mean time (
) for progression to cirrhosis was months. ‫ע‬SD 24.7 ‫ע‬ 5.6 ALT serum levels, CD4
ϩ cell count, and HIV RNA and HCV RNA serum levels. No significant changes were observed in ALT serum levels over time. In contrast, a significant increase in CD4 ϩ cell count and a concomitant decrease in the level of HIV RNA was observed over time in our cohort of patients coinfected with HIV and HCV who were treated with HAART (table 2) . In a subgroup of 76 patients, HCV RNA serum levels were available 12 and 24 months after initiation of HAART. As shown in table 2, no significant changes in HCV RNA levels were observed. Tables 3-5 show data for 3 subgroups of patients: patients who experienced immune restoration, patients who had ALT serum levels 14 times the normal values at initiation of HAART, and patients who had normal ALT levels at initiation of HAART. Patients with CD4 ϩ cell counts that increased at various times from levels р200 cells/mm 3 to levels у400 cells/mm 3 (immune restoration) showed a significant increase in ALT levels after 6 months of follow-up, but reduced ALT levels were observed between 6 and 12 months of follow-up (table 3) . However, in patients with immune restoration, changes in HCV RNA serum levels at 12 and 24 months were not significant.
Patients who had high ALT levels at the beginning of HAART showed a persistent and significant decrease in ALT levels after prolonged antiretroviral treatment (table 4) . In contrast, HCV RNA levels did not show any significant change, even though a significant decrease in ALT levels was correlated with persistently high levels of HCV RNA in 10 patients ( ). P p .0029 Finally, patients who had normal ALT values at the initiation of HAART showed a mild but persistent and statistically significant increase in ALT levels after prolonged antiretroviral treatment, despite the absence of significant changes in HCV RNA serum levels ( ) and a significant increase in CD4 ϩ cell counts P p .02 ( ). It is interesting to note that patients infected with P p .0006 HCV of genotype 1 had higher levels of HCV RNA before initiation of HAART than did patients infected with HCV of other genotypes ( ). P p .002
DISCUSSION
HIV coinfection is an important cofactor in HCV disease progression [21] . Eyster et al. [22] reported that HCV RNA levels increased 8-fold faster in patients with hemophilia who became infected with HIV than it did in patients who remained HIV negative, and liver failure occurred exclusively among patients coinfected with HIV and HCV. In addition, Darby et al. [23] showed that mortality associated with liver disease that developed after the exposure to HCV was 1.4% for HIV-negative subjects with hemophilia and 6.5% for HIV-infected subjects with hemophilia. On the other hand, Benhamou et al. [24] found that HIV coinfection was an independent risk factor for the development of cirrhosis in patients with hepatitis C. Before HAART became available, HIV infection was generally fatal [25] ; therefore, there could have been no more than 12 years of coinfection before liver failure occurred, which suggests that HIV infection shortens the typical 15-20-year natural history of hepatitis C. However, the mechanisms of accelerated liver injury have not yet been clarified. It has been postulated that HIV-associated immune dysfunction and cytokine up-regulation [26] may worsen the HCV-specific cytotoxic T cell response [27] . Because HAART may reverse HIV-induced immune dysregulation by reducing HIV load, it has been proposed that HAART has a beneficial effect on HCV disease and liver function [20] .
Some authors have reported the cases of patients who experienced acute hepatitis or severe hepatic necrosis after starting HAART [28, 29] . Furthermore, a few prospective studies showed the possibility of increase in HCV RNA serum levels after initiation of HAART, with no evident effects on ALT serum levels or liver function. However, these studies involved a limited number of patients and a short follow-up period [18, 19] .
In our retrospective study, the effectiveness of HAART was demonstrated by the significant increase in CD4 ϩ cell count and the decrease in HIV load. In spite of these findings, no significant changes were observed in ALT serum levels, which suggests that the overall influence of HAART on the clinical course of HCV infection is limited.
In accordance with the findings of other studies [30, 31] , our data show that HCV RNA serum levels are not modified in patients coinfected with HIV and HCV, whatever the effectiveness of HAART. However, in the group of patients who showed increased levels of ALT during HAART, the HCV RNA levels did not further increase. Ragni and Bontempo [32] have observed that, among patients with hemophilia who are coinfected with HIV and HCV, the HCV RNA increase that accompanies HAART does not lead to histopathologic worsening or progression of HCV disease.
The mortality observed was very low: only 4.6% of the patients died within 3 years of follow-up. Before HAART was available, the mortality of a comparable cohort of patients was approximately 5-10 times higher [25, 33, 34] . Other studies that evaluated the impact of HCV infection on survival of patients coinfected with HIV and HCV gave contrasting results [21, [35] [36] [37] . In our study, cirrhosis-related mortality accounted for more than one-third of all deaths, and analysis of survival curves did not show any significant difference between cirrhosis-related mortality and mortality due to other causes, including AIDS. This suggests that in the next few years cirrhosis may become the leading cause of death in patients coinfected with HIV and HCV.
Some intriguing considerations arise from the analysis of subgroups of patients with different responses to HAART or with different features of HCV disease. In patients with important immune restoration (increase in CD4 ϩ cell count from 2 to 4-5 times the basal level), a significant increase in ALT was observed at 6 months. This finding is consistent with the cases of hepatitis associated with immune restoration that were reported by John et al. [28] . A subsequent trend toward decreasing ALT levels was observed, suggesting that immune restoration may have beneficial long-term effects.
A persistent, significant decrease in ALT levels was observed in patients with high basal ALT levels at initiation of HAART. Because these patients are more likely to have active disease and more-severe liver damage than are patients with low ALT levels [38] , it is possible that immune restoration due to HAART may be beneficial in this group of patients, who may develop a stronger HCV-specific T cell cytotoxic response.
Finally, a mild but significant increase in ALT levels was observed in patients who had normal ALT levels at initiation of HAART. In this patient population, immune restoration due to HAART may compromise a temporary immunotolerance toward HCV, causing enhanced liver damage [39] . However, the possibility that an increase in ALT levels simply reflects HAART-related hepatotoxicity cannot be ruled out.
In conclusion, different effects of HAART associated with different characteristics of immune response and HCV disease may explain the contrast in the results that have been reported to date. However, larger, prospective studies based on the evaluation of changes in circulating HCV RNA and histological data are needed to clarify these issues.
